Skip to main content
Premium Trial:

Request an Annual Quote

Judy Lieberman, Patrice Courvalin

Premium
Cequent Pharmaceuticals announced that Harvard Medical School’s Judy Lieberman has joined its scientific advisory board.
 
Lieberman, well-known for her work in RNAi delivery, is a senior investigator at Harvard’s Immune Disease Institute.She holds a PhD in theoretical physics from Rockefeller Universityand an MD through the Harvard-Massachusetts Institute of Technology program in health, science, and technology.
 
Cequent also announced that Institut Pasteur professor Patrice Courvalin has also joined its SAB.
 
Courvalin is the head of the antibacterial agents unit at Institut Pasteur and holds a PhD in medical sciences from the University of Sciences in Paris.

The Scan

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.